Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 34

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 34
---
 ​ |     -7 | ​ |    -5 | ​ |     37 | ​ |    -21 | ​ |              333 | ​ |      5 | ​ |     8 | ​ |     17 | ​ |    -35 | ​ |   -35 | ​ |              39 | ​ |    -43 | ​ |   -41 |
| Other                           | ​ |     82 | ​ |    -19 | ​ |   -18 | ​ |      3 | ​ |    -46 | ​ |               59 | ​ |    -12 | ​ |   -11 | ​ |     18 | ​ |    -32 | ​ |   -33 | ​ |               2 | ​ |      8 | ​ |     7 |
| Other Medicines                 | ​ |    508 | ​ |     -9 | ​ |    -7 | ​ |     40 | ​ |    -23 | ​ |              392 | ​ |      2 | ​ |     4 | ​ |     35 | ​ |    -34 | ​ |   -34 | ​ |              41 | ​ |    -41 | ​ |   -40 |
| Total Medicines                 |   | 26,670 | ​ |      8 | ​ |    10 | ​ | 11,085 | ​ |     10 | ​ |            7,598 | ​ |      8 | ​ |    12 | ​ |  5,568 | ​ |      8 | ​ |     8 | ​ |           2,419 | ​ |      2 | ​ |     2 |

The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth.

45

Table 24: Product Sales year-on-year analysis: Q2 2025 (Unreviewed)

The Q2 2025 information in respect of the three months ended 30 June 2025 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP.

| ​                               
 ​                               
 For the half year ended 30 June | ​ 
 ​ 
 ​ |      ​ 
  World 
      ​ | ​ 
 ​ |      ​ 
 Change | ​ |     ​ | ​ 
 ​ 
 ​ |     ​ 
    US 
     ​ | ​ 
 ​ |      ​ 
 Change | ​ 
 ​